AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) investors are overwhelmingly excited today after the drug maker announced that following its meeting with thef FDA, on March …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced today that it has commenced a new “at-the-market” offering pursuant to its existing At Market Issuance (“ATM”) Sales …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) reported financial and operating results for the fourth quarter and year ended December 31, 2016.
Maxim analyst Jason Kolbert is optimistic on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) on the heels of the biotech firm indicating that the Pediatric …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that the Pediatric Committee (“PDCO”) of the European Medicines Agency (“EMA”) agreed to the Company’s Pediatric Investigation …
Maxim analyst Jason Kolbert weighed in on shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) with a $10.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that, following a comprehensive review of data obtained from the confirmatory Phase 3 clinical trial of Macrilen™ …
Shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) jumped over 20% today, after the drug maker announced the completion of the clinical phase of …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced the occurrence of the 384th death in the pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) …
Maxim analyst Jason Kolbert is out with a bullish research report today on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) just one week after the …
